• DiscoveryProbe Library: Evidence and Scope

  2026-10-16

  The DiscoveryProbe™ Bioactive Compound Library Plus is described by APExBIO as a 5,072-compound small-molecule collection spanning multiple biological pathway areas and supplied in a standardized research format. The available evidence supports a catalog-level account of its identity, claimed analytical quality controls, and conceptual screening scope, but no identity-matched study is available to establish product-specific biological performance, target engagement, or comparative assay outcomes.

• DiscoveryProbe Library: What the Record Supports

  2026-10-16

  The DiscoveryProbe™ Bioactive Compound Library Plus is described by APExBIO as a 5,072-compound research collection spanning many biological pathways. The available product information supports an overview of its identity, catalog-level mechanistic scope, formulation, and evidentiary limits, but no identity-matched paper is available to establish product-specific assay performance, effect sizes, or mechanism in a defined biological model.

• Lisinopril Dihydrate: Mechanism and Evidence Scope

  2026-10-15

  APExBIO describes lisinopril dihydrate as a commercial dihydrate form of the long-acting ACE inhibitor lisinopril, with a reported ACE IC50 of 4.7 nM and downstream effects on the renin–angiotensin system. Because no identity-matched research paper is available, these claims support a documented product and mechanism overview, not conclusions about model-specific efficacy, selectivity, or translational performance.

• Roscovitine: Mechanism and Evidence Boundaries

  2026-10-15

  Roscovitine, also known as Seliciclib or CYC202, is described by APExBIO as a cyclin-dependent kinase inhibitor with reported activity against several CDK complexes and weaker activity against ERK1/2. The same product description links it to late-prophase cell-cycle arrest in several nonmammalian models and reduced tumor-volume progression in A4573-bearing athymic nude mice, but it does not provide an identity-matched primary paper, complete study statistics, or evidence sufficient to establish clinical efficacy or universal target selectivity.

• AP1903: Evidence, Mechanism, and Scope

  2026-10-14

  AP1903 is described by APExBIO as a synthetic FKBP-binding ligand dimer for chemically induced dimerization of engineered FKBP fusion proteins. The product page reports assay-specific activity against F36V-FKBP, apoptosis in engineered HT1080 cells, and targeted cell ablation in mouse models. These claims define a conditional signaling tool, but the available product description does not provide the primary study details needed to assess comparators, uncertainty, construct design, or broader applicability.

• What the DLL3 circRNA CAR-T Study Shows

  2026-10-14

  Cai et al. report that transient, circRNA-encoded DLL3 CAR-T cells outperformed mRNA-encoded counterparts in cell and mouse models of small cell lung cancer. The findings support circRNA as a research platform for temporary CAR expression, but they do not establish clinical efficacy, safety, manufacturing readiness, or comparative advantage in patients.

• Thermal-Shift Screening and Library Evidence Boundaries

  2026-10-13

  Thermal-shift assays can help identify candidate ligands for bacterial sensor proteins, but a thermal transition is an indirect signal rather than proof of binding or receptor activation. The supplied 2025 review emphasizes false positives, false negatives, pH dependence and the need for orthogonal binding evidence. The DiscoveryProbe Bioactive Compound Library Plus is discussed only as a supplier-described chemical library; its catalog scope does not establish activity against any bacterial sensor or disease-relevant target.

• Thermal-Shift Screening and Its Evidentiary Limits

  2026-10-13

  A source-grounded overview of how thermal shift assays have been used to study bacterial sensor ligands, what the method can and cannot establish, and how a commercial compound library should be interpreted in that context.

• HNF4A, H. pylori and Gastric Cancer Epigenetics

  2026-10-12

  A 2025 study links Helicobacter pylori infection to promoter hypermethylation and silencing of HNF4A, a gastric epithelial tumor suppressor, with downstream loss of polarity and activation of EMT-associated signaling. The findings support a mechanistic model in experimental systems, but they do not establish that HNF4A methylation is the sole mediator of human gastric-cancer progression or that 5-Azacytidine was used in the study.

• Triiodothyronine and the Limits of the Evidence

  2026-10-12

  The supplied evidence describes Triiodothyronine (T3) as a thyroid hormone research reagent, while the cited 2026 study investigates spatially concentrated adenine base editors for a PLP1 mutation associated with Pelizaeus–Merzbacher disease. These sources address distinct biological questions and do not establish any role for T3 in the gene-editing findings.

• Amitriptyline HCl Product Overview

  2026-10-10

  A catalog-based overview of Amitriptyline HCl identity, reported target scope, and evidence limitations. No matched paper evidence or validated study outcomes were provided.

• β-Galactosidase Staining in HNSCC Senescence

  2026-10-09

  A source-grounded guide to what lysosomal β-galactosidase staining can show, how it relates to cellular senescence and cisplatin resistance in HNSCC, and why the signal should not be interpreted as a standalone biomarker.

• RepSox: ALK5 Inhibitor Evidence Guide

  2026-10-09

  RepSox is a vendor-described potent and selective ALK5 inhibitor with a reported IC50 of 4 nM. Peer-reviewed 2026 evidence supports an optimized small-molecule strategy for human iPSC-derived platelet production, but that study names 616452 rather than RepSox, so it does not directly establish RepSox activity in platelet differentiation.

• SMYD2, miR-125b, and RCC Drug Resistance

  2026-10-08

  A 2019 Theranostics study connected SMYD2 overexpression with clear cell renal cell carcinoma progression and multidrug resistance through a miR-125b/DKK3-associated regulatory axis. Its combined clinical, cellular, and xenograft evidence suggests that SMYD2 may serve as both a prognostic biomarker and a mechanistic entry point for studying chemotherapy response, although clinical translation remains unestablished.

• Difloxacin HCl and Checkpoint Biology

  2026-10-08

  Explore Difloxacin HCl through a disciplined comparison of bacterial DNA gyrase inhibition, antimicrobial susceptibility testing, and multidrug resistance reversal. A PNAS study on Plk1-regulated checkpoint disassembly provides a framework for interpreting mechanistic evidence without overextending cross-domain conclusions.

8067 records 2/538 page Previous Next 12345 下5页 Last page